New York, NY, Oct. 24, 2022 (GLOBE NEWSWIRE) — Deep Medicine Acquisition Corp. (Nasdaq: DMAQ) (the “Company”) today announced the appointment of Mr. John Chiang as a member of its Board of Directors, effective October 15, 2022.
Mr. Chiang has served on the board of directors of Apollo Medical Holdings, Inc. since January 2019 and the corporate advisory boards of Pasadena Private Lending, LLC since February 2019, Adept Urban since January 2021 and Calyx Peak Companies . since February 2019. From January 2015 to January 2019, Mr. Chiang served as California State Treasurer, where he oversaw financial transactions, investments and bond sales. Previously, Mr. Chiang served as California State Comptroller from January 2007 to January 2015.
Humphrey Polanen, Chairman of the Board and Chief Executive Officer of the Company, on behalf of the Board of Directors and management, said, “The DMAQ Board of Directors is delighted that John has chosen to bring his expertise and extensive experience as a statewide elected official of our corporation. As former Comptroller and Treasurer of the State of California, John Chiang has unique experience that will strengthen our Board of Directors.
About Deep Medicine Acquisition Corp.
DMAQ is a special purpose acquisition company formed for the purpose of entering into a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more companies or entities. DMAQ began trading on the Nasdaq in October 2021, and its common stock and rights trade under the ticker symbols DMAQ and DMAQR, respectively.
Caution Regarding Forward-Looking Statements
This press release may include, and oral statements made from time to time by representatives of the Company may include, “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1933. Exchange Act of 1934, as amended. Statements regarding possible business combinations and their financing, and related matters, and all other statements other than statements of historical facts included in this press release are forward-looking statements. When used in this press release, words such as “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “could”, “plan”, “possible”, “potential”, “predict”, “project”, “should”, “would” and similar expressions, insofar as they relate to us or to our management team, identify forward-looking statements. These forward-looking statements are based on the beliefs of management, as well as assumptions made by the management of the Company and information currently available to it. Actual results could differ materially from those contemplated by the forward-looking statements due to certain factors detailed in the Company’s filings with the Securities and Exchange Commission (“SEC”). All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the Company’s control, including those set forth in the Risk Factors section of the Company’s registration statement and the Company’s IPO prospectus. filed with the SEC. The Company assumes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Humphrey Polanen, Managing Director
Deep Medicine Acquisition Corp.
595 Madison Ave, 12th Floor
New York, NY 10017
Phone: (917) 289-2776
Copyright 2022 GlobeNewswire, Inc.